Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jingling Oral Liquid versus atomoxetine for pediatric ADHD
ChiCTR2300067856Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Jingling Oral Liquid and atomoxetine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Total score of the Children's ADHD RS-IV Parent Interview scale and change from baseline. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Jingling Oral Liquidatomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2300067856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067856.